Business
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025
Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2025. The full report can be found here. Chris Cargill, President and CEO of Nxera, commented: “During the third quarter of 2025, we made strong progress in advancing our plans for obesity and metabolic diseases, an area of strategic focus where we see excepti
About this update from Nxera Pharma Co., Ltd.
[{"type":"image","alt":"Nxera Pharma","displaySize":"","headline":null,"caption":"Nxera Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/3c5c5d1f11d2ca9444665ce7b9191638"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MMtO8FGLy1ULu25TBGkF3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3c5c5d1f11d2ca9444665ce7b9191638","width":300,"height":101}},"lazy":false},{"type":"text","content":"Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2025. The full report can be found here.","length":280,"tagName":"p"},{"type":"text","content":"Chris Cargill, President and CEO of Nxera, commented: “During the third quarter of 2025, we made strong progress in advancing our plans for obesity and metabolic diseases, an area of strategic focus where we see exceptional opportunity and have observed significant patient need. Our newly launched proprietary pipeline, led by our differentiated oral GLP-1 agonist and including multiple complementary GPCR-targeted programs, positions Nxera to play a leading role in shaping the next generation of metabolic therapies.","length":520,"tagName":"p"},{"type":"text","content":"“Meanwhile, our partnered programs continue to advance successfully with multiple milestones achieved across ongoing collaborations, notably with Centessa and its portfolio of orexin agonists, where there is growing industry interest in the orexin mechanism as a promising basis for novel therapies for sleep-wake disorders and other neurological conditions. These candidates were discovered using NxWave™ technology, reflecting the strength and versatility of our platform to generate novel molecules with potential to make meaningful therapeutic advances for patients. We also achieved a second important R&D milestone under our multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera. With this progress and a robust pipeline of data and milestones ahead, we are well positioned to close the year with strong momentum.”","length":902,"tagName":"p"},{"type":"t...